Tag: Celgene

Celgene Announce Better-than-Expected Profit

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla. Bristol-My...

New Deal of Celgene is for Blood Cancers Treatment

Celgene has struck another collaborative deal, even as the large pharmaceutical company is in the process of being folded into the operations of its new owner, Bristol-Myers Squibb. This morning, p...

Philogen Keeps Extending Relations

Philogen S.p.A., a privately-owned biotechnology company, through its wholly-owned Swiss subsidiary, Philochem AG, has announced two discovery collaborations. The first is with J&J’s biopharma ...

Celgene Keeps Making Pipeline Deals

Despite a looming takeover by Bristol-Myers Squibb, Celgene hasn’t stopped making pipeline-boosting deals. It’s just added two more partnerships for new drug and cell-based cancer immunotherapies. ...

BMS to Acquire Celgene for $74b

In a major biopharmaceutical shake-up, Bristol-Myers Squibb has announced that will acquire Celgene for $74 billion. The acquisition will create a combined speciality biopharma company with portfol...

Evotec and Celgene to collaborate on targeted protein degradation

Evotec AG announced that Evotec and Celgene Corporation have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation.

Celgene announced a live webcast in September

Celgene Corporation plans to present at two upcoming investor conferences where Celgene management will provide an overview of the company.

Takeda and Celgene invest in Presage Biosciences

Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing, announced that it has closed a Series D financing led by pharmaceutical companies Takeda and Celgene.

Celgene partnered with Skyhawk Therapeutics

Skyhawk Therapeutics announced collaboration with a Celgene Corporation to discover, develop and commercialize innovative small molecule treatment options for patients with neurological diseases.

Nativa received a license to use dependent invention

On June 1, 2018, the Moscow Arbitration Court satisfied the claim to issue a license for the use of a Celgene’s patent in respect of dependent invention, which Nativa LLC plans to use in the manufacturing of medicinal product.

Evotec and Celgene started oncology partnership

Evotec AG announced that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

Celgene and bluebird bio entered a new drug development agreement

bluebird bio, Inc. and Celgene Corporation announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen CAR T cell therapy.

Prothena starts collaboration with Celgene to develop new neuroscience therapies

drug development
Prothena Corporation, a biotechnology company focused on the discovery, development of therapies in the neuroscience, announced a collaboration with Celgene to develop new therapies for a range of neurodegenerative diseases.

Celgene and Vividion Therapeutics will jointly discover new medicines

Vividion Therapeutics, a biotechnology company using revolutionary proteomics and chemistry platforms, announced a strategic research collaboration with Celgene Corporation.

Celgene Corporation acquires Juno Therapeutics

Celgene Corporation and Juno Therapeutics, Inc. today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno

Celgene will launch a new research incubator

Celgene Corporation announced its plans to open the Thomas O. Daniel Research Incubator and Collaboration Center, offering entrepreneurs lab space, resources and support to scientists and companies